ClinicalTrials.gg
CompletedNCT03630315Updated Jul 10, 2024

CLN-0046: Treatment of AMD Subjects With OTX-TKI

A Phase 1 interventional study of OTX-TKI and OTX-TKI in Neovascular Age-related Macular Degeneration, sponsored by Ocular Therapeutix, Inc.. Completed at 6 sites in Australia. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by Ocular Therapeutix, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Macular Degeneration with a site in Australia — 17 open to participants now, 22 under way, 7 of them phase 3. Macular Degeneration · Australia.

Enrollment
59th of 66
29 · median 280
Started
2019
with 4 others
Phase 1
5 of 77
1 open now
Registered
30th of 77
by date

Among the 77 studies in Macular Degeneration with a site in Australia, this one is the 59th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2019, is one of 5 in phase 1, and was the 30th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

17 of the 77 studies in Macular Degeneration with a site in Australia are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Macular Degeneration with a site in Australia, or all of them as a file.
02

Study summary

To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).

Read the detailed description

A multi-center, dose escalation, Phase 1, safety, tolerability and efficacy study to evaluate three dose groups of the OTX-TKI implant to treat subjects with a diagnosis of primary subfoveal neovascularization secondary to AMD.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 50 years of age
  • Are eligible for standard therapy
  • Have active primary CNVM secondary to AMD, either newly diagnosed or previously treated with documented response to anti-VEGF therapy in the study eye [primary subfoveal CNV secondary to AMD including juxtafoveal lesions that affect the fovea] documented by FA and SD-OCT
  • Are female who is for at least 12 months prior to screening or surgically sterile; or male or female of willing to use two forms of adequate
  • Are able and willing to comply with all study requirements and visits

Exclusion criteria

Exclusion Criteria:

  • Have previous laser photocoagulation to the center of the fovea in the study eye
  • Have participated in any study involving an drug either in the U.S. or outside the U.S. within the past 30 days
  • Are an employee of the site that is directly involved in the management, administration, or support of the study, or be an immediate family member of the same
  • Have a presence of a disease other than CNVM due to AMD in the study eye that could affect vision or safety assessments
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Low Dose)

    Subjects will receive a low dose of OTX-TKI

    Drug: OTX-TKI

  • Experimental
    Cohort 2 (Middle Dose)

    Subjects will receive a middle dose of OTX-TKI.

    Drug: OTX-TKI

  • Experimental
    Cohort 3 (High Dose)

    Subjects will receive a high dose of OTX-TKI.

    Drug: OTX-TKI

  • Experimental
    Cohort 3 (Anti-VEGF)

    Subjects will receive OTX-TKI plus a single anti-VEGF injection

    Drug: OTX-TKI · Drug: Anti-VEGF

  • Experimental
    Cohort 4 (High Dose)

    Subjects will receive a high dose of OTX-TKI.

    Drug: OTX-TKI

  • Experimental
    Cohort 4 (Anti-VEGF)

    Subjects will receive OTX-TKI plus a single anti-VEGF injection

    Drug: OTX-TKI · Drug: Anti-VEGF

Interventions

  • OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • Standard of care therapy used to block vascular endothelial growth factor

    Also known as: aflibercept, bevacizumab, ranibizumab

  • OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • Standard of care therapy used to block vascular endothelial growth factor

    Also known as: aflibercept, bevacizumab, ranibizumab

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events for each subject

    All adverse events from screening through end of study will be captured

    Time frame: 9 months

Secondary outcomes

  1. Determine the Maximum Tolerated Dose of the OTX-TKI injection

    A Central Reading Center will evaluate multiple imaging modalities to confirm evidence of biological activity for subjects that have been treated with the OTX-TKI injection. If all subjects tolerate lower dosages, additional subjects will be treated at higher dosages. All data will be evaluated by the DSMC who, in concert with the Medical Monitor, will determine the Maximally Tolerated Dose.

    Time frame: 9 months

07

Study locations

6 sites
  • Ocular Therapeutix, Inc.
    Sydney, Site 1, Australia
  • Ocular Therapeutiux, Inc.
    Sydney, Site 2, Australia
  • Ocular Therapeutiux, Inc.
    Sydney, Site 3, Australia
  • Ocular Therapeutix, Inc.
    Adelaide, Australia
  • Ocular Therapeutix, Inc.
    Albury, Australia
  • Ocular Therapeutix, Inc.
    Melbourne, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jan 2024, 58 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 58 months is above that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2018
First posted
Aug 14, 2018
StartActual
Feb 18, 2019
Primary completionActual
Jan 10, 2024
CompletionActual
Jan 10, 2024
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03630315
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Feb 18, 2019
Primary completion
Jan 10, 2024
Completion
Jan 10, 2024
Last update
Jul 10, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion